The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Safety and efficacy of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma
Joshua Richter, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, discusses the safety and efficacy of linvoseltamab (REGN5458), a BCMA, CD3-directed bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Richter first highlights the dosing schedule used in this study, and then goes on to discuss the promising overall response rates and impressive toxicity profile of this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consultancy: Celgene/BMS, Secura Bio, Oncopeptides and Takeda; speakers bureau: Janssen, Sanofi and Adaptive Biotechnologies
Advisory Boards: Celgene/BMS, Janssen, Karyopharm, Sanofi, X4 pharmaceuticals, Oncopeptides, Adaptive Biotechnologies, Secura Bio and AstraZeneca
